Protective effects of angiotensin-converting enzyme inhibitors in high-risk African American men with coronary heart disease

Journal of Clinical Hypertension

Volumn 11, Issue 11, 2009, Pages 621-626

  Papademetriou, Vasilios ^a   Kaoutzanis, Christodoulos ^a   Dumas, Michael ^a   Pittaras, Andreas ^a   Faselis, Charles ^a   Kokkinos, Peter ^a   Fletcher, Ross D ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; HYPOCHOLESTEROLEMIC AGENT; LISINOPRIL; METOPROLOL; NIFEDIPINE; VERAPAMIL;

AFRICAN AMERICAN; AGED; ANGIOCARDIOGRAPHY; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DRUG EFFICACY; HEART CATHETERIZATION; HIGH RISK POPULATION; HOLTER MONITORING; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

AFRICAN AMERICANS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CORONARY DISEASE; FOLLOW-UP STUDIES; HEART CATHETERIZATION; HUMANS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RENIN-ANGIOTENSIN SYSTEM; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 70449365557     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2009.00174.x     Document Type: Article

References (17)

1. Alderman MH, Ooi WL, Cohen H. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens 1997, 10:1-8.
2. Blumenfeld JD, Sealey JE, Alderman MH. Plasma renin activity in the emergency department and its independent association with acute myocardial infarction. Am J Hypertens 2000, 13:855-863.
3. Dzau VJ. Mechanism of protective effects of ACE inhibition on coronary artery disease. Eur Heart J 1998, 19(suppl J):J2-J6.
4. Tsikouris JP, Cox CD. Pharmacologic blockade of the renin-angiotensin system: vascular benefits beyond commonly understood pharmacologic actions. Pharmacotherapy 2003, 23:1141-1152.
5. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation 1998, 97:1411-1420.
6. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987, 316:1429-1435.
7. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342:145-153.
8. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and the MICRO-HOPE sub-study. Lancet 2000, 355:253-259.
9. Dries DL, Exner DV, Gersh BJ. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 1999, 340:609-616.
10. Carson P, Ziesche S, Johnson G. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 1999, 5:178-187.
11. Julius S, Alderman MH, Beevers G. Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: The LIFE Study. J Am Coll Cardiol 2004, 43:1047-1055.
12. Dries DL, Strong MH, Cooper RS. Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. J Am Coll Cardiol 2002, 40:311-317.
13. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocer vs diuretic: The anti-hypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002, 288:2981-2997.
14. Wright JT, Dunn JK, Cutler JA. Outcomes in hypertensive black and non-black patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 2005, 293:1595-1608.
15. Weir MR, Gray JM, Paater R. Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. Hypertension 1995, 25:124-130.
16. Preson RA, Materson BJ, Reda DJ. Age-race subgroup compared with renin profile as predictors of blood pressure response to anti-hypertensive therapy. JAMA 1998, 280:1168-1172.
17. Saunders E, Weir MR, Kong BW. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990, 150:1707-1712.